BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2014 11:43:00 AM | Browse: 354 | Download: 463
Publication Name World Journal of Gastroenterology
Manuscript ID 11983
Country of Manuscript Source China
2014-06-16 10:02
Peer-Review Started
2014-06-16 11:18
To Make the First Decision
2014-06-27 17:32
Return for Revision
2014-07-02 17:36
2014-07-20 22:55
Second Decision
2014-08-28 10:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-08-28 10:39
Articles in Press
2014-08-28 10:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-09-10 04:28
Typeset the Manuscript
2014-11-08 16:51
Publish the Manuscript Online
2014-11-20 20:51
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Retrospective Study
Article Title Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture
Manuscript Source Unsolicited Manuscript
All Author List Shun-Zhen Zheng, De-Jie Liu, Ping Sun, Guang-Sheng Yu, Yan-Tian Xu, Wei Gong and Jun Liu
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81302124
Correspondence To Jun Liu, Professor, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun@hotmail.com
Keywords Sorafenib; Hepatocellular carcinoma; Spontaneous rupture; Efficacy; Safety
Core Tip Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening condition. Currently, sorafenib is available for HCC patients with spontaneous rupture, although its efficacy and safety have not been reported. This study aims to report the outcome of patients with ruptured HCC in a single center during a 5-year period. We retrospectively analyzed 32 patients who presented with ruptured HCC at our institute between 2008 and 2013. We concluded that sorafenib can be used in patients with ruptured HCC as it has interesting activity and is well tolerated. However, a larger prospective study is necessary to determine the efficacy of sorafenib in this group of patients.
Publish Date 2014-11-20 20:51
Citation Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol 2014; 20(43): 16275-16281
Url http://www.wjgnet.com/1007-9327/full/v20/i43/16275.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i43.16275
Full Article (PDF) WJG-20-16275.pdf
Full Article (Word) WJG-20-16275.doc
Revised Manuscript 11983-Review.doc
Peer-review Report 11983-Peer review.pdf
Answering Reviewers 11983-Answering reviewers.pdf
Scientific Misconduct Check 11983-CorssCheck.jpg
Scientific Editor Work List 11983-Scientific editor work list.pdf
Copyright License Agreement 11983-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 11983-Language certificate.PDF